HC Wainwright Issues Negative Estimate for TVTX Earnings

Travere Therapeutics, Inc. (NASDAQ:TVTX) – Research analysts at HC Wainwright dropped their Q2 2025 EPS estimates for Travere Therapeutics in a research note issued to investors on Tuesday, July 1st. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings of ($0.54) per share for the quarter, down from their prior forecast of ($0.38). HC Wainwright currently has a “Buy” rating and a $30.00 price target on the stock. The consensus estimate for Travere Therapeutics’ current full-year earnings is ($1.40) per share. HC Wainwright also issued estimates for Travere Therapeutics’ Q3 2025 earnings at ($0.62) EPS, Q4 2025 earnings at ($0.62) EPS, FY2025 earnings at ($2.30) EPS, FY2026 earnings at ($0.86) EPS, FY2027 earnings at ($0.17) EPS, FY2028 earnings at $0.13 EPS and FY2029 earnings at $0.47 EPS.

Travere Therapeutics (NASDAQ:TVTX) last issued its quarterly earnings results on Thursday, May 1st. The company reported ($0.47) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.08. Travere Therapeutics had a negative net margin of 82.88% and a negative return on equity of 1,179.73%. The company had revenue of $81.73 million during the quarter, compared to analyst estimates of $77.44 million. During the same period in the prior year, the business posted ($1.76) EPS. The business’s revenue for the quarter was up 83.3% compared to the same quarter last year.

Several other brokerages have also recently weighed in on TVTX. Guggenheim reaffirmed a “buy” rating and set a $47.00 target price on shares of Travere Therapeutics in a research note on Monday, April 14th. Canaccord Genuity Group lifted their price objective on shares of Travere Therapeutics from $45.00 to $47.00 and gave the stock a “buy” rating in a research note on Thursday, April 10th. Bank of America boosted their target price on shares of Travere Therapeutics from $29.00 to $31.00 and gave the stock a “buy” rating in a report on Tuesday, April 1st. Citigroup reduced their target price on shares of Travere Therapeutics from $35.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, June 11th. Finally, Stifel Nicolaus lifted their price target on shares of Travere Therapeutics from $22.00 to $23.00 and gave the stock a “hold” rating in a research report on Friday, May 2nd. Two investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $32.14.

Travere Therapeutics Stock Performance

TVTX opened at $15.00 on Thursday. Travere Therapeutics has a 1-year low of $7.72 and a 1-year high of $25.29. The company has a market capitalization of $1.33 billion, a price-to-earnings ratio of -5.34 and a beta of 0.72. The business has a 50 day moving average price of $16.72 and a two-hundred day moving average price of $18.13. The company has a debt-to-equity ratio of 9.46, a current ratio of 2.05 and a quick ratio of 2.03.

Insiders Place Their Bets

In other Travere Therapeutics news, CEO Eric M. Dube sold 18,924 shares of the stock in a transaction that occurred on Monday, May 5th. The shares were sold at an average price of $21.05, for a total value of $398,350.20. Following the completion of the sale, the chief executive officer owned 419,173 shares in the company, valued at $8,823,591.65. This represents a 4.32% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Peter Heerma sold 1,771 shares of Travere Therapeutics stock in a transaction on Monday, May 5th. The shares were sold at an average price of $21.05, for a total transaction of $37,279.55. Following the sale, the insider directly owned 128,215 shares of the company’s stock, valued at $2,698,925.75. This trade represents a 1.36% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 23,342 shares of company stock worth $485,753. 4.19% of the stock is currently owned by company insiders.

Institutional Trading of Travere Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of TVTX. Bank of New York Mellon Corp increased its position in Travere Therapeutics by 3.6% in the 4th quarter. Bank of New York Mellon Corp now owns 216,863 shares of the company’s stock worth $3,778,000 after purchasing an additional 7,513 shares during the last quarter. US Bancorp DE grew its stake in shares of Travere Therapeutics by 323.4% in the 4th quarter. US Bancorp DE now owns 31,795 shares of the company’s stock valued at $554,000 after buying an additional 24,286 shares in the last quarter. Charles Schwab Investment Management Inc. grew its stake in shares of Travere Therapeutics by 16.6% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 661,603 shares of the company’s stock valued at $11,525,000 after buying an additional 94,194 shares in the last quarter. Victory Capital Management Inc. acquired a new position in Travere Therapeutics in the fourth quarter worth approximately $182,000. Finally, Aigen Investment Management LP raised its position in Travere Therapeutics by 56.6% during the fourth quarter. Aigen Investment Management LP now owns 19,072 shares of the company’s stock valued at $332,000 after acquiring an additional 6,892 shares in the last quarter.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.